Free tool
FAERS Monitor: Tivicay
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204790 or its brand name (Tivicay, Dolutegravir Sodium). Reports on generic versions are filed under their own applications.
Reports
9,026
Serious
6,918
77% of reports
Hospitalization
1,965
Death reported
922
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain1,457
- anxiety1,059
- emotional distress1,050
- anhedonia944
- chronic kidney disease702
- exposure during pregnancy655
- fatigue649
- headache606
- off label use584
- renal failure546
- rash518
- foetal exposure during pregnancy483
- pyrexia475
- hypertension468
- drug ineffective433
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 25 |
| 2014 | 366 |
| 2015 | 532 |
| 2016 | 534 |
| 2017 | 563 |
| 2018 | 820 |
| 2019 | 1,135 |
| 2020 | 1,061 |
| 2021 | 926 |
| 2022 | 748 |
| 2023 | 792 |
| 2024 | 766 |
| 2025 | 472 |
| 2026 | 283 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 944 | 86.8 | 81.6 | 77,186 |
| exposure during pregnancySignal | 655 | 24.8 | 23.0 | 14,829 |
| chronic kidney diseaseSignal | 702 | 21.7 | 20.2 | 13,777 |
| emotional distressSignal | 1,050 | 20.4 | 19.2 | 19,273 |
| foetal exposure during pregnancySignal | 483 | 13.9 | 12.8 | 5,769 |
| renal failureSignal | 546 | 9.6 | 8.9 | 4,216 |
| anxietySignal | 1,059 | 8.7 | 8.2 | 7,281 |
| painSignal | 1,457 | 5.5 | 5.3 | 5,563 |
| hypertensionSignal | 468 | 5.2 | 4.7 | 1,577 |
| pyrexiaSignal | 475 | 3.2 | 2.9 | 728 |
| rashSignal | 518 | 2.8 | 2.5 | 596 |
| headacheSignal | 606 | 2.3 | 2.1 | 434 |
| fatigue | 649 | 1.9 | 1.8 | 307 |
| off label use | 584 | 1.6 | 1.4 | 120 |
| drug ineffective | 433 | 0.8 | 0.7 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.